Literature DB >> 2653211

Effect of attachment of anticandidal antibody to the surfaces of liposomes encapsulating amphotericin B in the treatment of murine candidiasis.

D R Hospenthal1, A L Rogers, E S Beneke.   

Abstract

The effect produced by antibody specific to Candida albicans when attached to liposomes containing amphotericin B was studied in vivo. Liposomal amphotericin B bearing specific immunoglobulin (LAMB-Ab) was compared with the unencapsulated drug (fAMB) and other liposomal amphotericin B formulations in the short-term survival (21 days) of mice with disseminated candidiasis. Both the treatment and prophylaxis of the murine model of candidiasis were explored in these trials. LAMB-Ab increased survival rates in the model more than other liposomal preparations containing amphotericin B. Liposomal amphotericin B compounds as a group prolonged survival over fAMB. Liposomal preparations used for comparison included liposomes with attached nonspecific antibody (LAMB-Ab-), liposomes without antibody (LAMB), and liposomes with unattached specific antibody (LAMB+).

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2653211      PMCID: PMC171413          DOI: 10.1128/AAC.33.1.16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  A GENERALIZED WILCOXON TEST FOR COMPARING ARBITRARILY SINGLY-CENSORED SAMPLES.

Authors:  E A GEHAN
Journal:  Biometrika       Date:  1965-06       Impact factor: 2.445

2.  The process of invasion and the persistence of Candida albicans injected intraperitoneally into mice.

Authors:  G YOUNG
Journal:  J Infect Dis       Date:  1958 Mar-Apr       Impact factor: 5.226

3.  Targeting of liposomes to accessible cells in vivo.

Authors:  G Gregoriadis; J Senior; B Wolff; C Kirby
Journal:  Ann N Y Acad Sci       Date:  1985       Impact factor: 5.691

4.  Causes of death in patients with malignant lymphoma.

Authors:  R Feld; G P Bodey; V Rodriguez; M Luna
Journal:  Am J Med Sci       Date:  1974-08       Impact factor: 2.378

5.  Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome-encapsulated amphotericin B.

Authors:  G Lopez-Berestein; R Mehta; R L Hopfer; K Mills; L Kasi; K Mehta; V Fainstein; M Luna; E M Hersh; R Juliano
Journal:  J Infect Dis       Date:  1983-05       Impact factor: 5.226

6.  Antibody-targeted liposomes: increase in specific toxicity of methotrexate-gamma-aspartate.

Authors:  T D Heath; J A Montgomery; J R Piper; D Papahadjopoulos
Journal:  Proc Natl Acad Sci U S A       Date:  1983-03       Impact factor: 11.205

Review 7.  Severe candidal infections: clinical perspective, immune defense mechanisms, and current concepts of therapy.

Authors:  J E Edwards; R I Lehrer; E R Stiehm; T J Fischer; L S Young
Journal:  Ann Intern Med       Date:  1978-07       Impact factor: 25.391

8.  Selective toxicity and enhanced therapeutic index of liposomal polyene antibiotics in systemic fungal infections.

Authors:  R L Juliano; G Lopez-Berestein; R Hopfer; R Mehta; K Mehta; K Mills
Journal:  Ann N Y Acad Sci       Date:  1985       Impact factor: 5.691

9.  Development of amphotericin B liposomes bearing antibody specific to Candida albicans.

Authors:  D R Hospenthal; A L Rogers; G L Mills
Journal:  Mycopathologia       Date:  1988-01       Impact factor: 2.574

10.  Effect of lipid composition and liposome size on toxicity and in vitro fungicidal activity of liposome-intercalated amphotericin B.

Authors:  F C Szoka; D Milholland; M Barza
Journal:  Antimicrob Agents Chemother       Date:  1987-03       Impact factor: 5.191

View more
  9 in total

1.  Improvement of amphotericin B activity during experimental cryptococcosis by incorporation into specific immunoliposomes.

Authors:  F Dromer; J Barbet; J Bolard; J Charreire; P Yeni
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

Review 2.  Amphotericin B: delivery systems.

Authors:  J Brajtburg; W G Powderly; G S Kobayashi; G Medoff
Journal:  Antimicrob Agents Chemother       Date:  1990-03       Impact factor: 5.191

Review 3.  Carrier effects on biological activity of amphotericin B.

Authors:  J Brajtburg; J Bolard
Journal:  Clin Microbiol Rev       Date:  1996-10       Impact factor: 26.132

Review 4.  Liposomes as delivery systems in the prevention and treatment of infectious diseases.

Authors:  J J Bergers; T L ten Hagen; E W van Etten; I A Bakker-Woudenberg
Journal:  Pharm World Sci       Date:  1995-01-27

5.  Amphotericin B lipid complex therapy of experimental fungal infections in mice.

Authors:  J M Clark; R R Whitney; S J Olsen; R J George; M R Swerdel; L Kunselman; D P Bonner
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

Review 6.  Biopharmaceutical aspects of lipid formulations of amphotericin B.

Authors:  G Storm; E van Etten
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-01       Impact factor: 3.267

7.  Enzyme immunoconjugates utilizing glucose oxidase and myeloperoxidase are cytotoxic to Candida tropicalis.

Authors:  D Casentini-Borocz; T Bringman
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

8.  Aerosolized amphotericin B-liposomes for treatment of systemic Candida infections in mice.

Authors:  B E Gilbert; P R Wyde; G Lopez-Berestein; S Z Wilson
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

9.  Treatment of systemic candidiasis in a neutropenic murine model using immunoglobulin G bearing liposomal amphotericin B.

Authors:  T Belay; D R Hospenthal; A L Rogers; M J Patterson
Journal:  Mycopathologia       Date:  1993-07       Impact factor: 2.574

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.